The Australasian Life Science Investment Summit (ALSIS) 2012, was again a major satellite event connected to Australia’s pre-eminent biotechnology industry conference, AusBiotech 2012, and was be held at the Melbourne Convention & Exhibition Centre on Friday 2 November 2012.
ALSIS was attended by 280 people, of which 150 were investors from 60 companies and almost 40% were international visitors who were here to find out more about 40 of Australia’s most promising biotechnology investment opportunities.
The audience featured an excellent mix of expertise from national and international investors, including angel investors, venture capitalists, fund managers, investment bankers and representatives from superannuation funds. The audience also included venture capital arms of the major pharmaceutical companies from Australia, Asia Pacific, North America and Europe.
Presenting companies featured be a mix of listed companies in late-stage development, private companies with identified product/opportunities and early-stage commercialisation companies from research institutes and universities.
ALSIS attendee Julie Phillips, CEO of showcased company BioDiem, said: “The Summit was a great chance to catch-up with colleagues, meet some new faces and share some ideas. It was a particularly good opportunity to showcase BioDiem with a large number of prospective investors.”
Marc Sinatra, analyst at Lodge Partners, said: “AusBiotech is always a good opportunity to catch up with the industry associates and meet new contacts from overseas. Australian biotechnology looks very healthy. It was heartening to see the very strong unlisted companies in the industry pipeline, as well as the maturing listed ones.”
“ALSIS is a great way to find new investment opportunities and catch-up on ones you haven’t seen for a while. It’s rare to get so many of the life-sciences investment community together, and I think attendees made the most of it.”
Click here for the final ALSIS program
Click here to view the company presentations via Open Briefing
